ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,836.22
      0.16%
      US Tech 100
      20,244.40
      -0.21%
      Dow Jones
      42,297.12
      0.86%
      Brent Oil
      80.22
      -0.49%
      Bitcoin
      93,722.06
      -0.81%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. UK
      5. LSE

      6. Vivoryon Therapeutics Nv (0R3M) Quote

      Vivoryon Therapeutics Nv

      Vivoryon Therapeutics Nv (0R3M)

      LSE
      4.71
      0.00
      (0.00%)
      Closed January 13 11:30AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      4.71
      Bid
      0.00
      Ask
      0.00
      Volume
      2,296
      0.00 Day's Range 0.00
      4.71 52 Week Range 4.71
      Market Cap
      -
      Previous Close
      4.71
      Open
      -
      Last Trade
      240
      @
      1.96
      (O)
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      4,467
      Shares Outstanding
      0.00
      Dividend Yield
      -
      PE Ratio
      0.00
      Earnings Per Share (EPS)
      -
      Revenue
      -3.62M
      Net Profit
      -28.34M

      About Vivoryon Therapeutics Nv

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.vivoryon.com
      Headquarters
      Halle, Deu
      Founded
      -
      Vivoryon Therapeutics Nv is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0R3M. The last closing price for Vivoryon Therapeutics Nv was 4.71 €. Over the last year, Vivoryon Therapeutics Nv shares have traded in a share price range of 4.71 € to 4.71 €.

      Vivoryon Therapeutics Nv currently has 0 shares outstanding.

      Ask ADVFN Intelligence (AI)

      0R3M Latest News

      More News

      Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

      Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function Vivoryon Therapeutics N.V. Presents Topline Phase...

      December 09 2024
      UK Regulatory

      Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

      Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress...

      December 04 2024
      UK Regulatory

      Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

      Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

      October 26 2024
      UK Regulatory

      Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

      Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

      October 11 2024
      UK Regulatory

      Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

      Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

      October 01 2024
      UK Regulatory

      Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

      Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

      September 12 2024
      UK Regulatory

      Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

      Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

      September 05 2024
      UK Regulatory

      Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

      Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

      September 05 2024
      UK Regulatory

      Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

      Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

      July 18 2024
      UK Regulatory

      Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

      Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on...

      July 09 2024
      UK Regulatory
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1004.714.714.716314.71DE
      4004.714.714.7114524.71DE
      12004.714.714.7144674.71DE
      26004.714.714.7169104.71DE
      52004.714.714.71123464.71DE
      156004.714.714.7159834.71DE
      260004.714.714.7142344.71DE

      0R3M - Frequently Asked Questions (FAQ)

      What is the current Vivoryon Therapeutics Nv share price?
      The current share price of Vivoryon Therapeutics Nv is 4.71 €
      What is the 1 year trading range for Vivoryon Therapeutics Nv share price?
      Vivoryon Therapeutics Nv has traded in the range of 4.71 € to 4.71 € during the past year
      What is the reporting currency for Vivoryon Therapeutics Nv?
      Vivoryon Therapeutics Nv reports financial results in EUR
      What is the latest annual turnover for Vivoryon Therapeutics Nv?
      The latest annual turnover of Vivoryon Therapeutics Nv is EUR -3.62M
      What is the latest annual profit for Vivoryon Therapeutics Nv?
      The latest annual profit of Vivoryon Therapeutics Nv is EUR -28.34M
      What is the registered address of Vivoryon Therapeutics Nv?
      The registered address for Vivoryon Therapeutics Nv is WEINBERGWEG 22, HALLE, 06120
      What is the Vivoryon Therapeutics Nv website address?
      The website address for Vivoryon Therapeutics Nv is www.vivoryon.com
      Which industry sector does Vivoryon Therapeutics Nv operate in?
      Vivoryon Therapeutics Nv operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BLUBlue Star Capital Plc
      8.25p
      (230.00%)
      		2.73M
      RCGHRc365 Holding Plc
      3.25p
      (54.76%)
      		8.11M
      BTCVinanz Limited
      22.50p
      (34.33%)
      		872.26k
      BANKFiinu Plc
      0.65p
      (30.00%)
      		2.26M
      TM1Technology Minerals Plc
      0.145p
      (20.83%)
      		26.39M
      NFXNuformix Plc
      0.045p
      (-25.00%)
      		157.31M
      EYEEagle Eye Solutions Group Plc
      362.00p
      (-23.14%)
      		173.99k
      GFINGfinity Plc
      0.0625p
      (-16.67%)
      		56.22M
      JWNGJaywing Plc
      0.525p
      (-16.00%)
      		728.76k
      SYMESupply@me Capital Plc
      0.003p
      (-14.29%)
      		133.24M
      TRPTower Resources Plc
      0.0355p
      (-10.13%)
      		1.96B
      ORCPOracle Power Plc
      0.018p
      (-5.26%)
      		300.79M
      LLOYLloyds Banking Group Plc
      53.28p
      (0.76%)
      		193.8M
      DGIDg Innovate Plc
      0.0185p
      (-7.50%)
      		171.19M
      NFXNuformix Plc
      0.045p
      (-25.00%)
      		157.31M

      Discussion

      View Full Feed
      k9uwa k9uwa 4 minutes ago
      I grabbed a few today 10.14 it is some that the shorts didn't and won't get.
      John k9uwa
      AVXL
      Eagle1 Eagle1 5 minutes ago
      Well, we all can agree to disagree here. Why can't you and Benz be friends? I disagree with him on some things, but I know that we are all on the same team because we are all invested heavy here.

      Fung, please just try to be our friend here and everyone get along.

      People
      GDVM
      bas2020 bas2020 5 minutes ago
      Yes, sometimes. Try exiting out of the browser (X), then open a new browser instance and go to history and restore the open tabs.
      NWBO
      price_and_volume price_and_volume 5 minutes ago
      Was that your point? I already made that point.

      It was in my post, and in the post I replied to.

      You asked if I know "where those 10b shares came from?"

      I'm curious what point YOU were trying to make?
      HMBL
      jimbo36 jimbo36 5 minutes ago
      I get what you are doing, but at some point throwing more dough to get out just gets more expensive.
      SAPX
      Smartypants2 Smartypants2 6 minutes ago
      Show the FACTS that XERI "can't get Nexboard certified after multiple failed attempts." IN FACT, no certification failure is cited in any reliable source! (Posts on IHub or similar sites by the same handful of anti-XERI posters don't count.)
      XERI
      glenn1919 glenn1919 7 minutes ago
      MNDR..................................https://stockcharts.com/h-sc/ui?s=MNDR&p=W&b=5&g=0&id=p86431144783
      MNDR
      Warmy Warmy 7 minutes ago
      Easy double money flip from 0.0001.
      GRLF
      MasterBlastr MasterBlastr 7 minutes ago
      So did you buy at 80 cents?
      LODE
      gitreal gitreal 7 minutes ago
      zero, nada and Zilch!!!!

      You're right! The first true thing you've ever posted on this board.

      I don't invest in scams. Apparently, you have no problem investing in scams and being an enabler. Shameful.
      NBRI
      BottomBounce BottomBounce 7 minutes ago
      Projections indicate NIO's stock could reach substantial increase from current levels. By 2030, some experts predict NIO's stock could trade in the range of $201.35 to $230.55, reflecting the company's potential to become a major player in the global EV industry. $NIO
      NIO
      Hoskuld Hoskuld 8 minutes ago
      The data has always been good. The trials have been poorly designed and executed - and the company refused to believe in itself enough to bet fully on 2-73 and 3-71 - but Anavex has the goods. They need to shed the small company thinking now - and I am betting they do it.

      What gave
      AVXL
      rosemountbomber rosemountbomber 8 minutes ago
      Another strong day for the stock price today whilst the overall market wasn't the greatest. Company issued a PR this morning highlights strong sales and estimates for peak sales for the two drugs. But realistically did not address what sales for X will be now in 2025 other than to say that it is n
      ARDX
      Jahvik Jahvik 8 minutes ago
      Of course they get them at a discount...don't know that I've ever seen shares issued in a transaction that weren't at a discount.

      HMBL
      Chartmaster Chartmaster 8 minutes ago
      575.35 low today was the low for another run to new highs imo
      SPY
      Reanimator Reanimator 9 minutes ago
      It clearly shows that the tech sector is hitting its limits, with rapidly growing AI demanding more and more

      Here we go again with the "Datacenters use a lot of energy!!! AI uses a lot of energy!!!! That automatically means that LWLG will be successful!!!!"

      I shouldn't
      LWLG
      Propain Propain 9 minutes ago
      Que sera, sera
      Whatever will be, will be
      The future's not ours to see
      Que sera, sera
      A...F...FU to zero.

      😃
      AFFU
      Hi_Lo Hi_Lo 9 minutes ago
      You conveniently ignored that you have posted 5100 times on Sharps shells in two years. Hundreds of hours over four years.
      And I've been correct about WNFT (which is more than can be said about you) and WNFT so far.

      Those are the only Sharp boards I post on...so it's hardly a
      WNFT
      glenn1919 glenn1919 9 minutes ago
      ZCAR...........................https://www.stockscores.com/charts/charts/?ticker=ZCAR
      ZCAR
      EternalPatience EternalPatience 9 minutes ago
      But still the daily portfolio growth by 50K+ looks good on paper (Just for Clark alone -- I have only 100 shares.. so my portfolio is growing by 25 dollars daily)
      FNMA
      Chartmaster Chartmaster 9 minutes ago
      BB stocks hit their lows today!!!
      Wingsjr Wingsjr 9 minutes ago
      Anyone who has a stop loss order on FnF is a paper hand 👧 🐶.
      FNMA
      fung_derf fung_derf 9 minutes ago
      I think I mentioned in the past why. I was trying to post to someone on a board I was booted from for questioning its validity. That person also posted here.
      Then I started getting stupid remarks from benz. Ya gotta agree, he's the worst! He tries to brag that he's buying so much stock, even
      GDVM
      Investor082 Investor082 9 minutes ago
      It won’t hit a $1. There will again be a ton of bag holders who will be left wondering why they didn’t sell on the spike when the opportunity presented itself and got too greedy hoping to exit at a $1.
      NWBO

      Your Recent History

      LSE
      0R3M
      Vivoryon Therapeutics Nv
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads